Study to Evaluate the Efficacy, Safety, and Tolerability of E7070 in Metastatic Breast Cancer Patients
Public ClinicalTrials.gov record NCT00080197. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label Phase II Study of E7070 in Metastatic Breast Cancer Patients Previously Treated With an Anthracycline, a Taxane, and Capecitabine
Study identification
- NCT ID
- NCT00080197
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Eisai Inc.
- Industry
- Enrollment
- 250 participants
Conditions and interventions
Conditions
Interventions
- E7070 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 31, 2004
- Primary completion
- Not listed
- Completion
- Apr 30, 2005
- Last update posted
- Oct 10, 2006
2004 – 2005
United States locations
- U.S. sites
- 34
- U.S. states
- 19
- U.S. cities
- 34
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Birmingham | Alabama | — | — |
| Not listed | Hoover | Alabama | — | — |
| Not listed | Sedona | Arizona | — | — |
| Not listed | Denver | Colorado | — | — |
| Not listed | Torrington | Connecticut | — | — |
| Not listed | Fort Myers | Florida | — | — |
| Not listed | Ocoee | Florida | — | — |
| Not listed | Tampa | Florida | — | — |
| Not listed | Chicago | Illinois | — | — |
| Not listed | Skokie | Illinois | — | — |
| Not listed | Urbana | Illinois | — | — |
| Not listed | Indianapolis | Indiana | — | — |
| Not listed | Overland Park | Kansas | — | — |
| Not listed | Minneapolis | Minnesota | — | — |
| Not listed | St Louis | Missouri | — | — |
| Not listed | Albany | New York | — | — |
| Not listed | Winston-Salem | North Carolina | — | — |
| Not listed | Kettering | Ohio | — | — |
| Not listed | Oklahoma City | Oklahoma | — | — |
| Not listed | Tulsa | Oklahoma | — | — |
| Not listed | Clairton | Pennsylvania | — | — |
| Not listed | Pittsburgh | Pennsylvania | — | — |
| Not listed | Wexford | Pennsylvania | — | — |
| Not listed | Greenville | South Carolina | — | — |
| Not listed | Austin | Texas | — | — |
| Not listed | Dallas | Texas | — | — |
| Not listed | Fort Worth | Texas | — | — |
| Not listed | Fredericksburg | Texas | — | — |
| Not listed | Houston | Texas | — | — |
| Not listed | Irving | Texas | — | — |
| Not listed | Tyler | Texas | — | — |
| Not listed | Fairfax | Virginia | — | — |
| Not listed | Spokane | Washington | — | — |
| Not listed | Vancouver | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00080197, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 10, 2006 · Synced Apr 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00080197 live on ClinicalTrials.gov.